Table 1.
Summary of the IC50 values of the tested compounds across a panel of cancer cells and human lymphocytes.
| IC50 (µM/L) | |||||
|---|---|---|---|---|---|
| Cisplatin (1) | 134 (2) | 138 (3) | TCAP(4) | Ligand | |
| A2780 | 0.2 ± 0.1 | 2.5 ± 0.2 | 1.8 ± 0.1 | 6.5 ± 0.3 | >100 |
| A2780cis | 16.8 ± 1.5 | 4.6 ± 0.2 | 1.5 ± 0.4 | 15.1 ± 0.6 | >100 |
| Toledo | 0.5 ± 0.07 | 0.5 ± 0.1 | 0.6 ± 0.04 | 8.8 ± 0.8 | >100 |
| Toledo-cis | 8.3 ± 0.6 | 2.9 ± 0.2 | 2.8 ± 0.1 | 12.6 ± 1.2 | >100 |
| Lymphocytes | 0.2 ± 0.1 | 3.4 ± 0.3 | 1.6 ± 0.1 | 11.9 ± 0.7 | >100 |
| Resistance Factor Defined as IC50(Resistant)/IC50(Sensitive) | |||||
| RF (IC50 A2780cis/IC50 A2780) | 84 | 1.8 | 0.8 | 2.3 | |
| RF (IC50 Toledo-cis/IC50 Toledo) | 17 | 5.8 | 4.6 | 1.4 | |